Everyone loves a good “this’ll cure Alzheimer’s!” story… both because we all know someone who has been touched by this awful disease, and because we know that a cure for Alzheimer’s would likely be a multi-billion-dollar drug. So the pundits tease early-stage hopefuls quite often, they fail almost all the time, and we keep hoping and coming back for more.
This time it’s Ray Blanco, again, teasing another potential Alzheimer’s Disease drug in ads for Ray Blanco’s Catalyst Trader ($1,995/yr “on sale” from $5,000, no refunds). And sadly, it’s one of those “this alert is so urgent, we couldn’t provide a transcript” video “presentations”… so I had to sit through the whole damn thing. If you’ve ever questioned how much I love you, dear readers, question no more.
I say “again” because we’ve heard similar tales spun by Blanco (and others) before — the ones that come to mind are Anavez (AVXL), which Blanco started teasing in 2015 or so with a prediction that the CEO would soon make an announcement that changes the face of modern medicine and ProMIS Neurosciences, which he expected to similarly have a miracle announcement about three years ago. Which serves, at least, to give us a little perspective — Anavex had a big surge early this year after nearly a decade of overpromising and disappointment, so it has just now gotten back to its 2015 highs, and the ProMIS share price is still below where it was three years ago.
And, of course, lots of folks have teased big fella Biogen (BIIB) for its aducanumab, which has been the most recent big hope in Alzheimer’s Disease, is likely to generate some huge headlines in the next week or so as the FDA has to finally decide whether or not they’ll approve the drug.
So what’s the target this time? Let’s see what clues he drops in the presentation — these are the quotes and notes I took on the fly, so I may have a small error here and there… here’s how the ad started:
“Based on new research from Harvard University, Columbia University, and the Kaiser Permanente Division of Research…
“Patent Application No. 057784:
“The Most Important Medical Breakthrough of the Century?
“This Revolutionary Patent Could Soon Unlock Life-Changing Wealth For Early Movers… Beginning As Soon As May 31, 2021”
In case you’re frustrated and about to tune out because of that date, have no fear: If there was going to be some big imminent news from the company, it did not come on May 31. Or June 1, so far. (And I may be speaking out of turn here, but I wouldn’t hold my breath about June 2).
What other verbiage can we feed to the Thinkolator?
“The treatment one small pharmaceutical company is developing could spark a revolution”
“Changing the way we think about Alzheimer’s’ altogether”
Other clues? Blanco says he spoke to the CEO of this “small biotech” in an “exclusive call,” so it’s a company that needs to be promotional — which is pretty much everyone in “small biotech” world.
The stock trades under $10 a share.
What does the drug do? Blanco says there’s a new line of thinking (from those name-dropped research labs and others) about how “plaque magnets” might be the real problem in Alzheimer’s Disease, not the amyloid beta plaque itself — that’s because higher levels of that “plaque magnet” causes the plaque to develop faster, and if we can lower the level of the magnets then not as much of the plaque will attach itself and start to clog up the system (OK, some of that’s my words.)
And he says that “Word of the studies has spread all over the media,” including these quotes:
“‘[Plaque magnet] levels linked to ALzheimer’s brain plaques’ CBS News
‘Popular [plaque magnet] meds may protect against Alzheimer’s’ Washington Post“
Neither of those is particularly new — they’re generally about the link between cholesterol and Alzheimer’s Disease, that CBS quote came from this article and the Post one originates here. Neither one is about this specific company teased, of course, but it gives you an idea of the theory they’re following.
Blanco also says that a Cornell study in mice found that using “donut shaped” rings of sugar molecules could trap plaque magnets, getting them away from the brain and letting the body expel them. So the general idea is, “did a company figure out if this will work in humans?”
Ray Blanco’s answer, as I hear it, seems to be that he’s never been as sure of anything else in his entire life… if you’re not trying to sell something, I’d say we’re still at “maybe.”
"reveal" emails? If not,
just click here...